Abbott Q4 2025 Earnings: Strategy and Growth Outlook

Abbott Laboratories recently published its financial results for the final quarter of 2025, highlighting a year of strategic growth despite some segment challenges. The company reported significant success in its medical device division, particularly with its glucose monitoring systems and new cardiac treatment approvals. While the nutrition business faced a downturn due to market share losses and pricing pressures, management plans to revitalize this area through numerous product launches and promotional shifts. A major highlight is the planned acquisition of Exact Sciences, a move intended to establish Abbott as a leader in the oncology screening market. Looking ahead to 2026, the firm expects double-digit earnings growth and improved profit margins. These reports also emphasize a commitment to shareholders through the 54th consecutive year of dividend increases.